All In Biotech

Drug Trial Radar · NCT05966493

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)

Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Aug 17, 2023

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Glaukos CorporationIndustry
Sponsor type
Industry
First posted
Jul 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.

Conditions

  • Persistent Corneal Epithelial Defect

Interventions

  • lufepirsen high doseDrug

    Lufepirsen is an unmodified connexin43 antisense oligonucleotide.

  • VehicleDrug

    Matching vehicle without lufepirsen.

  • lufepirsen low doseDrug

    Lufepirsen is an unmodified connexin43 antisense oligonucleotide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achieve Corneal Re-epithelialization Including Durability (CRC)Time frame: End of Study: 28 Days after achieving re-epithelialization

Locations

28 sites in 4 countries. Site status is shown where the registry gives one.

  • Glaukos Investigative Site

    Dothan, Alabama · Recruiting

  • Glaukos Investigative Site

    Petaluma, California · Recruiting

  • Glaukos Investigative Site

    Torrance, California · Recruiting

  • Glaukos Investigative Site

    Colorado Springs, Colorado · Recruiting

  • Glaukos Investigative Site

    Grand Junction, Colorado · Recruiting

  • Glaukos Investigative Site

    Bradenton, Florida · Recruiting

  • Glaukos Investigative Site

    Fort Myers, Florida · Recruiting

  • Glaukos Investigative Site

    South Miami, Florida · Recruiting

  • Glaukos Investigative Site

    Atlanta, Georgia · Recruiting

  • Glaukos Investigative Site

    Carmel, Indiana · Recruiting

  • Glaukos Investigative Site

    Fraser, Michigan · Recruiting

  • Glaukos Investigative Site

    Kansas City, Missouri · Recruiting

  • Glaukos Investigative Site

    Kansas City, Missouri · Recruiting

  • Glaukos Investigative Site

    Palisades Park, New Jersey · Recruiting

  • Glaukos Investigative Site

    Shelby, North Carolina · Recruiting

  • Glaukos Investigative Site

    Bala-Cynwyd, Pennsylvania · Recruiting

  • Glaukos Investigative Site

    Nashville, Tennessee · Recruiting

  • Glaukos Investigative Site

    Houston, Texas · Recruiting

  • Glaukos Investigative Site

    San Antonio, Texas · Recruiting

  • Glaukos Investigative Site

    Madison, Wisconsin · Recruiting

  • Glaukos Investigative Site

    Milwaukee, Wisconsin · Recruiting

  • Glaukos Investigative Site

    Mainz, Germany · Recruiting

  • Glaukos Investigative Site

    München, Germany · Recruiting

  • Glaukos investigative Site

    Messina, Italy · Recruiting

  • Glaukos Investigative Site

    Barcelona, Spain · Recruiting

  • Glaukos Investigative Site

    Madrid, Spain · Recruiting

  • Glaukos Investigative Site

    Seville, Spain · Recruiting

  • Glaukos Investigative Site

    Zaragoza, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.